Urothelial Carcinoma: Histologic Variants
On this page
Direct answer
Urothelial carcinoma frequently departs from its usual papillary and nested morphology, and the WHO 2022 classification codifies these variants because several change management outright. The five with therapeutic bite: micropapillary carcinoma (small papillary clusters with reverse nuclear polarity, heavy lymphovascular invasion, early cystectomy debated even at T1); plasmacytoid carcinoma (single Indian-file cells with plasma-cell-like eccentric nuclei, E-cadherin loss from CDH1 alteration, peritoneal spread, poor survival); nested carcinoma including its large-nested form (deceptively bland von Brunn-like glands that infiltrate deeply); sarcomatoid carcinoma (biphasic malignant epithelial and spindle components, homologous or heterologous); and small-cell neuroendocrine carcinoma (platinum-etoposide responsive, PSA-unrelated biology in the prostate analogy). Divergent squamous and glandular differentiation is common and simply reported as a percentage.
What you must remember
- Micropapillary hallmark: tight epithelial clusters within retraction spaces, nuclei apically oriented toward the stroma (reverse polarity), and lymphovascular invasion in most resections; BCG failure is expected and upfront cystectomy is advocated by many for T1 disease.
- Plasmacytoid marker logic: loss of membranous E-cadherin; cells infiltrate as single files and lacuna-like chains in the lamina propria, mimicking chronic inflammation or lobular breast metastasis; peritoneal carcinomatosis is characteristic.
- Nested and large nested: small regular nests with minimal atypia — the diagnostic give-away is deep infiltration into or beyond muscularis propria at low power; large nested variant nests exceed about 1 mm yet remains deceptively bland.
- Sarcomatoid carcinoma: malignant spindle plus epithelial components; heterologous elements (osteosarcoma, chondrosarcoma, rhabdomyosarcoma) are named; behaves high-grade regardless of sampling.
- Small-cell carcinoma: neuroendocrine markers (synaptophysin, chromogranin, INSM1), CK20 dot-like positivity possible; treated with platinum-etoposide regimens rather than urothelial chemotherapy alone.
- Rhabdoid and lymphoepithelioma-like variants: rhabdoid tumours lose SMARCB1/INI1; lymphoepithelioma-like carcinoma — undifferentiated cells in a dense lymphocytic backdrop — is unusually chemotherapy-responsive, PD-L1 rich and among the better-prognosis variants.
- Reporting discipline: name the variant, estimate its percentage, assess depth (lamina propria versus muscularis propria) and lymphovascular invasion — variant plus muscle invasion changes neoadjuvant and cystectomy conversations.
- Urothelial lineage markers: GATA3, uroplakin II and III, p63 and CK7 keep the diagnosis urothelial when morphology is unrecognisable; squamous differentiation in endemic schistosomal regions (chiefly Africa and the Middle East) still produces pure squamous carcinoma.
Deciding on a T1 micropapillary tumour
A 66-year-old man undergoes transurethral resection for a large lateral-wall tumour. Histology shows conventional high-grade papillary urothelial carcinoma overlying a micropapillary component infiltrating lamina propria, 30% of the tumour, with lymphovascular invasion and no muscularis propria in the deepest sections. The staging is T1 with an important asterisk: the specimen lacks muscle in the critical zone, mandating a repeat resection regardless of therapy choice.
The tumour board conversation now departs from standard T1 management. Micropapillary histology at T1 responds poorly to intravesical BCG, with progression rates that persuaded many guidelines toward early radical cystectomy with neoadjuvant cisplatin-based chemotherapy rather than a BCG trial. The pathology report's percentage estimate (30% micropapillary) enters the decision because even minor components confer risk, and the lymphovascular invasion finding strengthens the case. Had the same depth shown nested variant instead, the challenge would be diagnostic rather than therapeutic: confirming invasion into muscularis propria with a basal-cell-sparing, p53-aberrant nested proliferation is what prevents the catastrophic under-grade of a lethal tumour.
Where students slip
The classic slip is reading the lamina propria in a plasmacytoid tumour as "chronic inflammation with plasma cells" — the single-file architecture and enlarged hyperchromatic nuclei, plus E-cadherin loss, mark carcinoma. The second is dismissing bland nested glands as von Brunn nests: von Brunn nests live in the superficial lamina propria with lobular architecture and maintain association with the urothelium; nested carcinoma reaches muscularis propria. The third exam error is treating variant histology as descriptive garnish — the mark-scoring sentence is that micropapillary, plasmacytoid and sarcomatoid variants alter therapy and prognosis, while squamous or glandular differentiation is reported but does not usually change the urothelial treatment platform. Indian viva angle: be ready to name which variants justify early cystectomy and which justify chemotherapy-first (small-cell, lymphoepithelioma-like).
Frequently asked questions
What defines the micropapillary variant?
Small papillary clusters in clear retraction spaces with reverse nuclear polarity toward the stroma, high lymphovascular invasion rates and poor BCG response.
Which adhesion marker is lost in plasmacytoid carcinoma?
E-cadherin, reflecting CDH1 alterations — the molecular correlate of its discohesive single-file infiltration and peritoneal spread pattern.
Why is nested variant carcinoma dangerous?
Its deceptively bland nests mimic benign von Brunn nests, so it is frequently under-graded; deep infiltration into muscularis propria betrays its aggressive nature.
What defines sarcomatoid urothelial carcinoma?
Biphasic malignant epithelial and spindle-cell components, potentially with heterologous osteosarcomatous or chondrosarcomatous differentiation, behaving as high-grade disease.
How is small-cell carcinoma of the bladder treated?
With platinum plus etoposide chemotherapy regimens — neuroendocrine rather than urothelial biology, with cystectomy reserved for local control in selected patients.